<?xml version="1.0" encoding="UTF-8"?>
<article-meta class="article-meta">
 <article-id pub-id-type="pmcid" class="article-id">5789983</article-id>
 <article-id pub-id-type="publisher-id" class="article-id">20325</article-id>
 <article-id pub-id-type="doi" class="article-id">10.1038/s41598-018-20325-0</article-id>
 <article-categories class="article-categories">
  <div subj-group-type="heading" class="subj-group" xmlns="http://www.w3.org/1999/xhtml">
   <span class="subject">Article</span>
  </div>
 </article-categories>
 <title-group class="title-group">
  <div class="article-title" xmlns="http://www.w3.org/1999/xhtml">Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry</div>
 </title-group>
 <div class="contrib-group" xmlns="http://www.w3.org/1999/xhtml">
  <contrib contrib-type="author" class="contrib" xmlns="">
   <name class="name">
    <span class="surname" xmlns="http://www.w3.org/1999/xhtml">Tavares</span>
    <span class="given-names" xmlns="http://www.w3.org/1999/xhtml">Ana Beatriz M. L. A.</span>
   </name>
   <a href="#Aff1" xmlns="http://www.w3.org/1999/xhtml">*</a>
  </contrib>
  <contrib contrib-type="author" class="contrib" xmlns="">
   <span contrib-id-type="orcid" class="contrib-id" xmlns="http://www.w3.org/1999/xhtml">http://orcid.org/0000-0001-6428-811X</span>
   <name class="name">
    <span class="surname" xmlns="http://www.w3.org/1999/xhtml">Lima Neto</span>
    <span class="given-names" xmlns="http://www.w3.org/1999/xhtml">José X.</span>
   </name>
   <a href="#Aff1" xmlns="http://www.w3.org/1999/xhtml">*</a>
  </contrib>
  <contrib contrib-type="author" class="contrib" xmlns="">
   <name class="name">
    <span class="surname" xmlns="http://www.w3.org/1999/xhtml">Fulco</span>
    <span class="given-names" xmlns="http://www.w3.org/1999/xhtml">Umberto L.</span>
   </name>
   <a href="#Aff1" xmlns="http://www.w3.org/1999/xhtml">*</a>
  </contrib>
  <contrib contrib-type="author" corresp="yes" class="contrib" xmlns="">
   <span contrib-id-type="orcid" class="contrib-id" xmlns="http://www.w3.org/1999/xhtml">http://orcid.org/0000-0002-1022-1048</span>
   <name class="name">
    <span class="surname" xmlns="http://www.w3.org/1999/xhtml">Albuquerque</span>
    <span class="given-names" xmlns="http://www.w3.org/1999/xhtml">Eudenilson L.</span>
   </name>
   <div class="address" xmlns="http://www.w3.org/1999/xhtml">
    <span class="email">eudenilson@gmail.com</span>
   </div>
   <a href="#Aff1" xmlns="http://www.w3.org/1999/xhtml">*</a>
  </contrib>
  <aff id="Aff1" class="aff" xmlns="">
   <div class="institution-wrap" xmlns="http://www.w3.org/1999/xhtml">
    <span institution-id-type="ISNI" class="institution-id">0000 0000 9687 399X</span>
    <span institution-id-type="GRID" class="institution-id">grid.411233.6</span>
    <span class="institution">Departamento de Biofísica e Farmacologia, </span>
    <span class="institution">Universidade Federal do Rio Grande do Norte, </span>
   </div>59072-970 Natal, RN Brazil 
  </aff>
 </div>
 <pub-date pub-type="epub" class="pub-date">
  <span class="day" xmlns="http://www.w3.org/1999/xhtml">30</span>
  <span class="month" xmlns="http://www.w3.org/1999/xhtml">1</span>
  <span class="year" xmlns="http://www.w3.org/1999/xhtml">2018</span>
 </pub-date>
 <pub-date pub-type="pmc-release" class="pub-date">
  <span class="day" xmlns="http://www.w3.org/1999/xhtml">30</span>
  <span class="month" xmlns="http://www.w3.org/1999/xhtml">1</span>
  <span class="year" xmlns="http://www.w3.org/1999/xhtml">2018</span>
 </pub-date>
 <pub-date pub-type="collection" class="pub-date">
  <span class="year" xmlns="http://www.w3.org/1999/xhtml">2018</span>
 </pub-date>
 <span class="volume" xmlns="http://www.w3.org/1999/xhtml">8</span>
 <span class="elocation-id" xmlns="http://www.w3.org/1999/xhtml">1840</span>
 <history class="history">
  <date date-type="received" class="date">
   <span class="day" xmlns="http://www.w3.org/1999/xhtml">2</span>
   <span class="month" xmlns="http://www.w3.org/1999/xhtml">10</span>
   <span class="year" xmlns="http://www.w3.org/1999/xhtml">2017</span>
  </date>
  <date date-type="accepted" class="date">
   <span class="day" xmlns="http://www.w3.org/1999/xhtml">16</span>
   <span class="month" xmlns="http://www.w3.org/1999/xhtml">1</span>
   <span class="year" xmlns="http://www.w3.org/1999/xhtml">2018</span>
  </date>
 </history>
 <div class="permissions" xmlns="http://www.w3.org/1999/xhtml">
  <span class="copyright-statement">© The Author(s) 2018</span>
  <div license-type="OpenAccess" class="license">
   <div class="license-p">
    <span class="bold">Open Access</span> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit 
    <span ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" class="ext-link" xmlns:xlink="http://www.w3.org/1999/xlink">http://creativecommons.org/licenses/by/4.0/</span>.
   </div>
  </div>
 </div>
 <div id="Abs1" class="abstract" xmlns="http://www.w3.org/1999/xhtml">
  <p id="Par1">Much of the recent excitement in the cancer immunotherapy approach has been generated by the recognition that immune checkpoint proteins, like the receptor PD-1, can be blocked by antibody-based drugs with profound effects. Promising clinical data have already been released pointing to the efficiency of the drug pembrolizumab to block the PD-1 pathway, triggering the T-lymphocytes to destroy the cancer cells. Thus, a deep understanding of this drug/receptor complex is essential for the improvement of new drugs targeting the protein PD-1. In this context, by employing quantum chemistry methods based on the Density Functional Theory (DFT), we investigate in silico the binding energy features of the receptor PD-1 in complex with its drug inhibitor. Our computational results give a better understanding of the binding mechanisms, being also an efficient alternative towards the development of antibody-based drugs, pointing to new treatments for cancer therapy.</p>
 </div>
 <div class="custom-meta-group" xmlns="http://www.w3.org/1999/xhtml">
  <div class="custom-meta">
   <span class="meta-name">issue-copyright-statement</span>
   <span class="meta-value">© The Author(s) 2018</span>
  </div>
 </div>
</article-meta>
